Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Case Rep Oncol Med
Egile Nagusiak: Roberto, Michela, Bassanelli, Maria, Iannicelli, Elsa, Giacinti, Silvana, D'Antonio, Chiara, Aschelter, Anna Maria, Marchetti, Paolo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Hindawi Publishing Corporation 2015
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4698998/
https://ncbi.nlm.nih.gov/pubmed/26798533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/629046
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak